Targeting TCTP with sertraline and thioridazine in cancer treatment

Robert Amson, Christian Auclair, Fabrice André, Judith Karp, Adam Telerman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

We have initially demonstrated in knocking down experiments that decreasing TCTP in cancer cells leads in some tissues to cell death while in others to a complete reorganization of the tumor into architectural structures reminiscent of normal ones. Based on these experiments and a series of other findings confirming the key role of TCTP in cancer, it became important to find pharmacological compounds to inhibit its function, and this became for us a priority. In the present text, we explain in detail the experiments that were performed and the perspectives of sertraline in cancer treatment, as this became today a reality with a clinical study that started in collaboration with Columbia University and Johns Hopkins University.

Original languageEnglish (US)
Title of host publicationResults and Problems in Cell Differentiation
PublisherSpringer Verlag
Pages283-290
Number of pages8
DOIs
StatePublished - 2017

Publication series

NameResults and Problems in Cell Differentiation
Volume64
ISSN (Print)0080-1844
ISSN (Electronic)1861-0412

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Targeting TCTP with sertraline and thioridazine in cancer treatment'. Together they form a unique fingerprint.

Cite this